PharmaReports: Psychiatric, Addictive & Sleep Disorders
LeadDiscovery offers full reports in selected areas of the pharmaceutical and biotech sector.
Each of the reports below has been especially selected by LeadDiscovery. Browse the reports or try our search engine.
This channel focuses on the main psychiatric diseases such as depression, bipolar disease, anxiety and schizophrenia although reports focusing on neuroelectrophysiology (for example epilepsy) are also included here. Likewise reports relating to addictive, sleep and attention deficit disorders are also included here.
Showing results 1 - 50 of 92
- Psychotherapeutics: Antidepressants, Antipsychotics, Antianxiety Drugs, World Market
- The Impact of the Phase III Pipeline: Future Projections and Market Disruptions
- Smoking Cessation and Addiction Treatments: A World Market Analysis
- Alzheimer disease - new drugs, markets and companies
- Drug Delivery in Central Nervous System Diseases - technologies,markets and companies
- The World Sleep Disorders Market, 2005-2010
- The World Schizophrenia Market 2005-2010
- The World Market for Antidepressants, 2006
- Anti-addiction Therapies, 2006-2011
- Pipeline Insight: Insomnia - Targeting the sleep maintenance market
- Pipeline Insight: Depression - Novel drugs to grow third-line market
- Early Toxicology: Markets and Approaches
- Biotech Drug Delivery Systems - Key Company Intelligence & Market Outlook to 2012
- Bipolar Disorder - New treatments for bipolar depression set to drive near-term growth
- Parkinson's Disease and Restless Legs Syndrome - Reformulations set to drive near-term growth
- Pipeline Insight: Schizophrenia
- From Blockbuster to Nichebuster
- Monoclonal Antibodies 2007
- The Global Protein Therapeutics Market
- Biogenerics
- Major Depressive Disorder - Duloxetine - Fulfilling An Unmet Need?
- Pipeline Insight: Anxiety Disorders - A decade of declining revenues
- Therapeutic Vaccines
- Pipeline and Commercial Perspectives: Insomnia
- Cognitive Impairment in Schizoaffective Disorder
- Pipeline Insight: ADHD
- Monoclonal Antibodies: Financial and strategic analysis of the mAb market
- Commercial Insight: Depression -Atypical lifecycle management strategy rejuvenates depression market
- Insomnia Strong brand identity critical to differentiation in an increasingly crowded market
- Irritable Bowel Syndrome - A potentially profitable market with limited competition
- Drug Discovery Tools for High-Content Analysis
- Personalized Medicine
- ANXIETY - Therapy Area Pipeline Report
- DEMENTIA - Therapy Area Pipeline Report
- DEPRESSION - Therapy Area Pipeline Report
- INSOMNIA and SLEEP DISORDERS - Therapy Area Pipeline Report
- SCHIZOPHRENIA - Therapy Area Pipeline Report
- IRRITABLE BOWEL SYNDROME (IBS) - Therapy Area Pipeline Report
- SMOKING CESSATION - Therapy Area Pipeline Report
- Global Smoking Cessation Market Analysis & Forecasts - Preparing for the First Blockbuster
- Top Companies and Products in the RNA/DNA Therapy Products Market
- Anti-Obesity Treatments 2007-2012 - A blockbuster market
- Analysis of the Pharmaceutical Market to 2012 - Segmented by Drug Target Family
- Biosimilars Series: Strategic issues - Potential remains uncertain
- Translational Medicine in Biopharmaceutical Research and Development
- The CNS Market Outlook
- Pipeline Report - Neuronal alpha 7 nicotinic receptors: Candidates for the treatment of Alzheimers disease and Schizophrenia
- The Gastrointestinal Market Outlook to 2012
- Pipeline Insight: Orphan Diseases in CNS - Huntington's Disease
- Licensing Strategies - Current Pharmaceutical Licensing Trends
Browse our theraputic areas for other entries:
- Oncology
- Cancer Immunotherapy
- Immunology & Inflammatory Diseases
- Infectious Diseases
- Psychiatric, Addictive & Sleep Disorders
- Pain
- Neurodegenerative & Neuroelectrophysiological Disorders
- Metabolic & Hormonal Disorders
- Cardiovascular Disorders
- GenitoUrinary Tract Disorders
- Technology
- Diagnostics & Devices
- Other Theraputic Areas, Pharmaceutical Strategy and Development